NCT00854152已完成1 期
An Open-label, Phase I, Dose-Escalation Study Evaluating the Safety, Tolerability, and Maximally Tolerated Dose of GDC-0980 Administered Once Daily in Patients With Refractory Solid Tumors and Non-Hodgkin's Lymphoma
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 121
- 主要终点
- Occurrence of adverse events
研究概览
简要总结
This is an open-label, multicenter, Phase I study to evaluate the safety, tolerability, and pharmacokinetics of escalating oral doses of GDC-0980 administered to patients with incurable, locally advanced or metastatic solid malignancy or NHL that has progressed or failed to respond to at least one prior regimen or for which there is no standard therapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically documented, incurable, locally advanced or metastatic solid malignancies, or NHL without leukemic phase, that has progressed despite standard of care therapy or for which there is no standard therapy of proven clinical benefit
- •ECOG performance status of 0 or 1 at screening
- •Evaluable or measurable disease per RECIST and/or the following: prostate cancer patients with non-measurable disease are eligible if they have two rising prostate-specific antigen (PSA) levels that meet the PSA Working Group criteria for progression prior to initiation of study treatment; ovarian cancer patients with non-measurable disease are eligible if they have two rising CA-125 levels greater than the ULN >= 2 weeks apart prior to initiation of study treatment.
- •Life expectancy >=12 weeks
- •Adequate hematologic and organ function within 14 days before initiation of GDC-0980
- •Documented willingness to use an effective means of contraception for both men and women while participating in the study
排除标准
- •Leptomeningeal disease as the only manifestation of the current malignancy
- •History of Type 1 or 2 diabetes mellitus requiring regular medication
- •Grade >= 2 hypercholesterolemia or hypertriglyceridemia
- •Ejection fraction that is <50% or below the LLN (whichever is higher), as determined by echocardiogram or MUGA scan
- •DLCO < 50% of predicted value corrected for hemoglobin and alveolar volume prior to initiation of GDC-0980
- •Malabsorption syndrome or other condition that would interfere with enteral absorption
- •Known untreated malignancies of the brain or spinal cord, or treated brain metastases that are not radiographically stable for >= 3 months
- •Active congestive heart failure or ventricular arrhythmia requiring medication
- •Active infection requiring IV antibiotics
- •Requirement for any daily supplemental oxygen
- •Uncontrolled hypomagnesemia
- •Hypercalcemia requiring continued use of bisphosphonate therapy
- •Clinically significant history of liver disease, including viral or other hepatitis, current alcohol abuse, or cirrhosis
- •Uncontrolled ascites requiring frequent paracentesis
- •Known HIV infection
- •Any other diseases, active or controlled pulmonary dysfunction, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug
- •Significant traumatic injury within 4 weeks of Day 1
- •Major surgical procedure within 4 weeks prior to initiation of GDC-0980
- •For all patients participating in Stage 2: Prior treatment with any PI3K inhibitor, mTOR inhibitor or dual PI3K/mTOR inhibitor. For HNSCC patients, this restriction applies only to any PI3K inhibitor, mTOR inhibitor, or dual PI3K/mTOR inhibitor used in the palliative setting.
- •Treatment with chemotherapy, hormonal therapy (except hormone replacement therapy, oral contraceptives, or GnRH agonists or antagonists for prostate cancer), immunotherapy, biologic therapy, radiation therapy (except palliative radiation to bony metastases), or herbal therapy as cancer therapy within 3 weeks prior to initiation of GDC-0980
- •Palliative radiation to bony metastases within 2 weeks prior to initiation of GDC-0980
- •Need for chronic corticosteroid therapy of >= 10 mg of prednisone per day or an equivalent dose of other anti-inflammatory corticosteroids or immunosuppressant
- •Treatment with an investigational agent within 4 weeks prior to initiation of GDC-0980
- •Unresolved toxicity from prior therapy except for alopecia and Grade 1 peripheral neuropathy
- •Pregnancy or lactation
- •For patients participating in DCE-MRI assessments, any contraindication to MRI examination
- •For patients with advanced solid tumors or NHL participating in the PPI-effect assessment: Known hypersensitivity to rabeprazole, substituted benzimidazoles, or to any component of the formulation
研究组 & 干预措施
1
Experimental
干预措施: GDC-0980 (Drug)
结局指标
主要结局
Occurrence of adverse events
时间窗: Length of study
Occurrence of dose-limiting toxicities
时间窗: Length of study
PK parameters after doses of GDC-0980
时间窗: Length of study
Occurrence of Grade 3 and 4 abnormalities in safety-related laboratory parameters and associated dose of GDC-0980
时间窗: Length of study
次要结局
- Best overall response, duration of objective response, and progression-free survival for patients with measurable disease(Length of study)
研究者
相似试验
已完成
1 期
A Study Evaluating the Safety and Tolerability of GDC-0068 in Patients With Refractory Solid TumorsSolid CancersNCT01090960Genentech, Inc.52
已完成
1 期
A Study Evaluating GDC-0980 Administered Once Weekly in Patients With Refractory Solid Tumors or Non-Hodgkin's LymphomaNon-Hodgkin's Lymphoma, Solid CancersNCT00854126Genentech, Inc.38
已完成
1 期
A Study of GDC-0941 in Participants With Locally Advanced or Metastatic Solid Tumors for Which Standard Therapy Either Does Not Exist or Has Proven Ineffective or IntolerableSolid CancersNCT00876109Genentech, Inc.108
已完成
1 期
A Dose-Escalation Study of GDC-0994 in Patients With Locally Advanced or Metastatic Solid TumorsSolid TumorNCT01875705Genentech, Inc.40
进行中（未招募）
1 期
To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast CancerSolid TumorBreast CancerNCT03006172Genentech, Inc.200